The General Hospital Corporation;Genzyme Corporation
发明人:
James B. STREISAND,Jesse D. ROBERTS, JR.
申请号：
US14139332
公开号：
US20140199399A1
申请日:
2013.12.23
申请国别(地区):
US
年份:
2014
代理人:
摘要：
The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-β antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-β antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.
